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Abstract
In carcinogenesis, determination of gene and protein expression profiles is important for prevention and treatment.
Caffeic acid phenethyl ester (CAPE) in a single dose administered before carcinogenic initiation induced by diethyl-
nitrosamine (DEN) prevents the appearance of preneoplastic lesions. On the basis of this approach, the main pur-
pose of this work was to compare the gene expression profiles induced by DEN or a previously administered single
dose of CAPE. Using a modified hepatocarcinogenesis-resistant hepatocyte model, male Fischer-344 rats were ad-
ministeredwith one intraperitoneal dose of CAPE (20mg/kg) 12 hours before DEN administration (200mg/kg). Livers
were removed and processed for microarray analysis and reverse transcription–polymerase chain reaction 12 hours
after CAPE dosing and 24 hours after DEN administration with or without CAPE. CAPE alone did not alter the expres-
sion profile. DEN treatment modified the expression of 665 genes, and CAPE plus DEN induced changes in 1371
genes. DEN treatment increased the expression of genes associated with oxidative stress such as glutathione
reductase, genes involved in cell cycle regulation including p53, and modified cytochrome P450. CAPE plus DEN
diminished the expression of cytochrome involved in DEN bioactivation such as CYP2B1 as well as the expression
of regulators of oxidative stress such as glutathione reductase, GST-κ and GST-θ, and cell cycle regulators such as
p53. Using CAPE as a tool, we uncovered new approaches for studying the altered expression of reactive genes and
identifying proteins that will help to propose well-sustained and concrete hypothesis of DENmechanism of hepato-
carcinogenesis initiation.
Translational Oncology (2010) 3, 142–148
Introduction
Exposure to chemical carcinogens is one of the most studied areas in
carcinogenesis, and three major stages in carcinogenesis have been
recognized: initiation, when mutations occur and initiated cells are
generated; promotion, when clonal expansion of initiated cells takes
place and forms preneoplastic lesions; and progression, when preneo-
plastic lesions become tumors through the gain of additional genetic
and metabolic alterations [1].
Diethylnitrosamine (DEN), an environmental carcinogen, has
been used in several experimental models [2]. Specifically, it has been
used as an initiator in the modified resistant hepatocyte model [3,4]
because initiation is necessary for carcinogenesis [5]. This effect has
not yet been completely studied, with only a few elements of the
pathway having been identified thus far. As early as 3 hours after
DEN administration, lipid peroxidation can be detected [6], as well
as overexpression of glutathione-S -transferase Pi (GST-p) at 4 hours;
this is considered a marker of initiation in chemical carcinogenesis and
tumors [7]. In addition, the formation of DNA adducts have been de-
tected as early as 3 hours after administration [8], and generalized necro-
sis clearly seen after 24 hours is a sign of subsequent damage [5,9].
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In themodified resistant hepatocyte model of hepatocarcinogenesis,
it has been demonstrated that oxidative stress is necessary for initiation.
When N -ethyl-N -nitrosourea is used as the initiator carcinogen in-
stead of DEN, it generates the same adducts as DEN, but without
an important oxidative stress. When N -ethyl-N -nitrosourea is used,
preneoplastic lesions are not observed at 25 days, in contrast to the high
number that occurs when oxidative stress and adducts are produced by
DEN. This finding is also supported by the decreased induction of
preneoplastic lesions by the antioxidant quercetin [6]. Oxidative stress
generated during the initiation stage is mainly due to DEN metabo-
lism by cytochrome P450 (CYP). DENmust bemetabolized by several
CYP family members to produce the active procarcinogen, and when
the isoforms related to this bioactivation are inhibited by a chemo-
protector such as caffeic acid phenethyl ester (CAPE), the lesions
observed in the model are drastically reduced [5,10].
As previously shown in the modified resistance hepatocyte model,
three stages are necessary to produce preneoplastic lesions at 25 days
and liver cancer after 7 months of initiation [5,11]. As such, all com-
ponents of this model (DEN, 2-acetyl aminofluorene administration
and partial hepatectomy) are necessary, and it is implied that each has
an individual pathological mechanism; however, the specific mecha-
nisms of each step in carcinogenesis process remain unclear.
Gene expression profile (GEP) of the progression stage has shown
important genetic changes related to the evolution of liver preneo-
plastic lesions toward neoplastic lesions and tumors [11]. However,
GEP and possible expression modifications by anticancer agents have
not been extensively studied.
The chemoprotectors quercetin, celecoxib, and CAPE are inhibitors
of the initiation stage and prevent preneoplastic lesions; CAPE is one
of the most efficient inhibitors. When administered 12 hours before
DEN, this natural component of propolis diminished tissue damage
produced 24 hours after DEN administration, as well as lipid perox-
idation and modification of CYP isoforms 1A1/2 and 2B1/2 related to
DEN bioactivation. All of these alterations are thought to be related to
the reduced incidence of preneoplastic lesions at 25 days after DEN
treatment in CAPE-pretreated animals [5,11].
Thus, the aim of this work was to analyze the initiation stage using
microarrays to contrast the changes in GEP produced by DEN alone
with those produced when CAPE was administered before DEN. We
have hypothesized that the comparison of the carcinogenic treatment
versus the chemoprotector plus carcinogen will show relevant changes
in gene expression pertaining to the initiation of carcinogenesis.
Results indicated that there is a differential effect on GEP induced
by CAPEwith or without DEN.When CAPEwas administered alone,
it did not modify GEP. After DEN administration, 665 genes were
modulated and CAPE plus DEN modified surprisingly 1371 genes.
CAPE modulated several cell physiological aspects, such as DEN
metabolism, regulation of oxidative stress, and others such as prolifer-
ation, DNA replication, and DNA repair. These results proposed new
routes to study the principal events performed in the initiation of
hepatocarcinogenesis process and in the chemoprotector action
mechanism of CAPE.
Materials and Methods
Animals
Male Fischer-344 rats (180-200 g) were obtained from the Unit for
Production of Experimental Laboratory Animals (UPEAL Cinvestav,
Mexico City, Mexico). Animals had access to food (PMI Feeds, Inc,
Laboratories Diet, Richmond, IN) and water ad libitum, with each
rat consuming approximately 12 to 15 g of food and 10 to 15 ml of
water per day. Animals were maintained in a holding room under
controlled conditions of 12-hour light/dark cycles, 50% relative hu-
midity, and 21°C. Animal care followed institutional guidelines for
the use of laboratory animals.
Experimental Protocol
Animals were administered 200 mg/kg DEN (Sigma-Aldrich,
St Louis, MO) as in the modified resistant hepatocyte model of
Semple-Robert [3]. A group of rats was pretreated with a 20-mg/kg
single dose of CAPE (kindly provided by Dr. Javier Hernández-
Martínez, CIAD, Hermosillo, Mexico) 12 hours before DEN treat-
ment [10]. Animals were killed 12 hours after CAPE alone and
24 hours after DEN administration with and without CAPE. Animals
were killed by exsanguination. Livers were excised, washed in physio-
logical saline solution, frozen in 2-methyl butane with liquid nitrogen,
or immersed in RNAlater (Sigma) and stored at −80°C. Frozen livers
sections were used to complementary DNA (cDNA) microarray and
reverse transcription–polymerase chain reaction (RT-PCR) assays (n = 4
in each group).
cDNA Microarray Slides
Microarrays were assayed at the Biochips Platform of Genopole,
University of Toulouse, INSA, UPS, INP & INRA (Toulouse,
France). cDNA hybridization was performed on slides with 28,800
spots using 27,004 oligonucleotides of 22,012 rat genes, includ-
ing 5000 genes with known function in the rat. Data were analyzed
with the Web service Bioplot, Bioclust, and Venn diagrams from
Transcriptome-Biochips Platform of Genopole Toulouse Midi-
Pyrenees (http://biopuce.insa-toulouse.fr). Altered genes were selected
using a ratio of up-regulation threshold greater than 1.5, down-
regulation threshold less than 0.6, and Student’s t test with P < .05
considered statistically significant. The generated data set has been
submitted to the National Center for Biotechnology Information
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo/index.cgi) database (GSE12030).
Relative Quantitative RT-PCR
Total RNA extraction was performed using Tripure Isolation Re-
agent (Roche Diagnostics, Indianapolis, IN). DNAse treatment was
performed using RNase-free DNAse I (Roche Diagnostics), and
cDNA synthesis was performed using SuperScript Reverse Transcrip-
tase (Invitrogen, Carlsbad, CA). Real-time PCR was performed in a
LightCycler Carousel-Based System Instrument 2.0 (Roche Diagnos-
tics) using LightCycler FastStart DNA MasterPLUS SYBR Green I
(Roche Diagnostics), and primers were synthesized by Invitrogen
(Table 1). RT-PCR was performed in quadruplicate, and additional
reactions were performed without reverse transcriptase to verify the
absence of DNA contamination. Gene expression quantification was
performed using a derivation of the 2−ΔΔCT method, 2
−ΔC ′
T [12].
Student’s t test was used as statistical analysis.
Results
Differential GEPs in Liver Cancer Initiation
Considering that omission of the carcinogen initiator is sufficient
to avoid preneoplastic lesions and cancer induction [5], molecular
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alterations at the initiation stage are likely necessary for cancer to
occur. To characterize the GEP modifications that occur at the initi-
ation stage, microarray analyses were performed to determine genes
differentially expressed on DEN, CAPE, or CAPE plus DEN ad-
ministration. At 24 hours after DEN administration, 665 genes were
transcriptionally modified; of these, 160 had known function in
the rat, with 91 upregulated and 69 downregulated. The effect
of CAPE was analyzed at 12 hours after administration; this elapsed
period before DEN administration was used to determine GEP
changes produced by the chemoprotector alone. As such, CAPE ad-
ministration did not induce modifications in the GEP. When CAPE
was administered 12 hours before DEN and its effect evaluated
24 hours after DEN treatment, the expression of 1371 genes was
changed; 343 of these have known function in the rat. Of these
genes, 100 were upregulated and 243 were downregulated. Of the
160 altered genes with known function in the rat, 38 were restored
to normal levels, 122 remained altered with DEN treatment alone,
and the expression of 221 was newly modified in the CAPE plus
DEN group (Figure 1). It is tempting to speculate that genes whose
expression was initially modified by DEN were restored by CAPE
treatment thus describing a chemoprotective mechanism for CAPE.
Upregulated Genes
A general analysis of GEP was the starting point for this study. In
the DEN-treated group, 91 genes were upregulated; of these, 66 re-
mained modified after CAPE treatment (Table W1), whereas the
expression of 25 was restored to untreated levels (Table W2). The
91 genes modified by DEN included several ribosomal proteins,
CYP, heat shock proteins, and genes such as GAPDH and GST-κ, sug-
gesting an important alteration of protein synthesis, metabolism,
and oxidative stress, which are all involved the initiation stage
(Table W1). In the CAPE plus DEN group, 100 genes were upregu-
lated; of these, 66 were upregulated after DEN treatment (Table W1)
and 34 were only upregulated after CAPE plus DEN administration
(Table W3). These 34 genes encode ribosomal proteins as well as heat
Table 1. Primers Used in RT-PCR.
Symbol Gene ID Forward Reverse Size (bp)
CYP1A2 NM_012541 AGGGACACCTCACTGAATGG CCGAAGAGCATCACCTTCTC 182
CYP2A2 NM_012693 ATCCAGATGTGGAAGCCAAG CCACGGAAGGTTGTGTTCTT 187
CYP2B1 NM_001134844 GGAAGCTCTGGTTGCTTGAC CAAAGAAGTGCAGACCGACA 206
CYP2E1 NM_031543 CCTACATGGATGCTGTGGTG CTGGAAACTCATGGCTGTCA 171
GST-θ NM_012796 ATGGCATTCCCTTTCAGTTG GTGGTCTGCCACCTGGTACT 179
GST-κ NM_181371 CACGGAGTCCCAGAACATTT CGGTCAGACCCAAATAGCAT 210
p53 NM_030989 TCTCCCAGCAAAAGAAAAA CTTCGGGTAGCTGGAGTGAG 168
p38 NM_031020 AGCGATACCAGAACCTGTCC GAACGTGGTCATCGGTAAGC 318
YY1 NM_173290 GACGACGACTACATCGAGCA TTGATCTGCACCTGCTTCTG 209
DNApolδ NM_021662 GACGACGACTACATCGAGCA AGCGGGAGGAGAAGAGTAGG 217
GLUTATHION REDUCTASE NM_053906 CCATGTGGTTACTGCACTTCC GTTCCTTTCCTTCTCCTGAGC 171
These genes were selected from microarrays analysis and validated by RT-PCR.
Figure 1. Venn diagram of transcriptionally altered genes. Data were
analyzed using the Venn diagram program from http://biopuce.
insa-toulouse.fr. Genes were identified as upregulated (threshold >
1.5) or downregulated (threshold < 0.6) with P < .05 considered
statistically significant with Student’s t test (n = 4 in each group).
Figure 2. Comparison of Venn diagrams for genes upregulated or
downregulated after DEN or DEN plus CAPE treatment. (A) Upregu-
lated genes, threshold greater than 1.5 with P < .05 by Student’s
t test. (B) Downregulated genes, threshold less than 0.6 with P <
.05 by Student’s t test. Data were analyzed using the Venn diagram
program from http://biopuce.insa-toulouse.fr (n= 4 in each group).
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shock proteins and CYP, among others. In line with chemoprotective
effects of CAPE, there were differences between in GEPs between
both groups (Figure 2A).
Downregulated Genes
After DEN treatment, 69 genes were downregulated, and 56 genes
remained downregulated after CAPE treatment (Table W4). Of these,
the expression of 13 was restored to control levels by CAPE adminis-
tration before DEN (Table W5). Within the set of downregulated
genes, there were several CYP isoforms as well as microglobulins, macro-
globulins, VEGFR1, and APC. In general, gene down-regulation was a
hallmark of CAPE pretreatment because CAPE plus DEN treatment
downregulated 243 genes, of which 56 were common to the DEN
alone condition and 187 genes were downregulated independently
of DEN administration (Table W6), including ribosomal proteins,
CYP, globulins, p53, p38, transcription factor YY1, GST-θ, and others.
It should be noted that some CYP family members were down-
regulated in the CAPE plus DEN group, including bioactivators of
DEN such as CYP2E1, CYP2B1, CYP1A2; this suggests that CAPE
treatment might affect DEN bioactivation. In addition, CAPE might
act by modifying the cell cycle, oxidative stress, and other pathways
involved in cell regulation (Figure 2B).
PCR Validation
The aim of using microarrays was to explore the GEP to generate
hypothesis about events involved in tumor initiation. Microarrays are
completely reliable because the genes are not individually evaluated.
Thus, microarray results must be validated using a quantitative
method. For RT-PCR validation, we selected 11 genes (Table 2): four
related to DEN metabolism (CYP2E1, 2B1, 1A2, and 2A2), three
related to oxidative stress regulation (GST-κ, GST-θ, and glutathione
reductase), and four related to cell regulation (transcription factor
YY1, DNA polymerase δ [DNA polδ ], p53, and p38). We found that
DEN administration decreased CYP2E1, 1A2, and 2A2 expression,
but CAPE administration did not ameliorate this effect. Conversely,
CYP2B1 expression was not altered by DEN, but at 24 hours after
DEN treatment, CAPE administration significantly decreased the
expression of this isoform (Figure 3). The expression of GST-κ,
GST-θ, and glutathione reductase genes increased with DEN adminis-
tration and decreased in the CAPE plus DEN group (Figure 4). DEN
treatment increased YY1, p53, and DNA polδ expression; this effect
decreased with CAPE pretreatment. DEN reduced the expression of
Table 2. Genes Validated by RT-PCR for Microarray Results.
Gen Function
CYP2B1*
CYP1A2* DEN metabolism
CYP2A2*
CYP2E1
GST-κ†
GST-θ* Oxidative stress regulation
GLUTATIÓN REDUCTASE *
YY1*
DNA polδ * Replication
p53* DNA reparation
p38* Cell signaling process.
* Genes downregulated by CAPE plus DEN as determined by microarray.
† Genes upregulated by DEN as determined by microarray.
Figure 3. RT-PCR validation ofCYP expression levels. Samples were analyzed by RT-PCR using primers described in Table 1.CAPE indicates
rats killed 12 hours after CAPE dosing;D+C24, killed 24 hours after DEN dosingwith CAPE pretreatment 12 hours before DEN (n=4 in each
group); D24, killed 24 hours after DEN dosing; NT, untreated. *P< .05 compared with NT, **P< .05 compared with D24 by Student’s t test.
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p38 and CAPE had no effect (Figure 5). This suggests that CAPE
modulates the alterations produced by DEN at different levels. Fur-
thermore, these results confirm the importance of microarray valida-
tion, because on RT-PCR analysis, the expression of some genes was
not in complete agreement with microarray data. We also observed ex-
pression changes that were not observed when using the microarray,
such as increased expression of YY1, p53, and DNA polδ genes.
Discussion
Chemoprevention is helpful for preventing or even curing cancer in
any of the three stages of carcinogenesis: initiation, promotion, or pro-
gression. To this end, CAPE has been studied for the past 20 years, and
it has shown chemoprotective properties in several types of cancer.
In different experimental models, the mechanism of action differs de-
pending on the situation tested [4,5,10,12–19]. In the modified resis-
tant hepatocyte model of liver cancer, the chemoprotective mechanism
of action of CAPE in the initiation stage is not completely understood,
but it seems to be related to the inhibition of DEN bioactivation [5].
The initiation stage is a necessary step in the modified resistant
hepatocyte model. Initiation is caused by DEN administration. The
metabolites produced during bioactivation produce mutations in
DNA, generate oxidative stress, and, finally, initiate cells toward trans-
formation. Furthermore, oxidative stress and DNA alkylation have
both been suggested to be necessary for initiation [6]. During the
first 24 hours after DEN administration, the expression of the tumor
marker GST-p is observed, and lipid peroxidation, adduct formation,
CYP modifications, and tissue damage are also detected [5–8]. These
alterations thus represent a phenotype characteristic of initiated hepa-
tocytes. However, it is important to identify the immediate early
changes in hepatocarcinogenesis to uncover specific molecular targets
for detection and chemoprevention.
Microarray analysis is a powerful technique for genetic and genomic
investigation, making it possible to simultaneously analyze gene ex-
pression of thousand of genes [20]. This is important, considering that
gene expression variations are associated with common diseases and
do not lead directly to disease, but instead generate an intermediary
molecular phenotype. Therefore, it is important to identify the molec-
ular phenotypes associated with changes in disease state. In this
manner, molecular networks that involve changes in disease can be
elucidated [21].
We used microarray slides with 28,800 spots, allowing for a large
and complex data set to be analyzed. It was necessary to further select
a small group of genes to validate. We started with genes with well-
known function in rats. From the analysis of 28,800 spots, we identi-
fied genes expressed differentially in each treatment; 160 were modified
by DEN, 343 by DEN plus CAPE, and none by CAPE alone before
DEN administration.
To validate microarrays by RT-PCR, we selected three groups of
genes related to specific functions in the rat liver that could be involved
in the initiation process. Genes that 1) might be involved in the initi-
ation of carcinogenesis, 2) are directly involved in the initial oxidative
stimulus that modifies the phenotype of hepatocytes, and 3) activate
possible proliferation signals through DNA alkylation were selected.
The first genes selected were those related to DEN bioactivation be-
cause alteration of DENmetabolism should result in altered initiation.
Gene expressions of 1A2, 2E1, and 2A2 isoforms were diminished by
DEN treatment and were not modified by CAPE pretreatment. The
expression of 2B1 was not affected by DEN but was significantly re-
duced by pretreatment with CAPE alone and by administration of
both CAPE and DEN. Because CYP2B1 is an important bioactivator
of DEN, we propose that DEN bioactivation by CYP2B1 is dimin-
ished by CAPE, as previously shown enzymatically [5].
The second group of genes selected were those involved in oxidative
stress regulation including GST-κ, a mitochondrial GST isoform,
GST-θ, a cytosolic isoform, and glutathione reductase [22]. These genes
were upregulated by DEN treatment in agreement with the previous
report of altered redox state [6]. The messenger RNA up-regulation of
Figure 4. RT-PCR validation of GST-κ, GST-θ, and glutathione reduc-
tase (GR) expression levels. Samples were analyzed by RT-PCR
using primers from Table 1. CAPE indicates rats killed 12 hours
after CAPE dosing; D + C24, killed 24 hours after DEN dosing with
CAPE pretreatment 12 hours before DEN (n = 4 in each group);
D24, killed 24 hours after DEN dosing; NT, untreated. *P < .05
compared with NT, **P < .05 compared with D24 by Student’s
t test.
146 Gene Expression in Liver Cancer Initiation Beltrán-Ramírez et al. Translational Oncology Vol. 3, No. 2, 2010
these genes was not present with CAPE pretreatment alone or in the
CAPE plus DEN group. This suggests that pretreatment-derived
counteraction of oxidative stress is likely related to the decreased bioac-
tivation of DEN; this effect is likely derived from the reduced gener-
ation of oxidative stress by CYP together with the direct antioxidant
activity of CAPE [10]. Both mechanisms deserve further analysis be-
cause there is a need to identify new candidates as possible initiation
markers during the early stages of carcinogenesis, such as GST-p [7].
The third group of selected genes was related to cell regulation pro-
cesses such as proliferation and DNA repair. The transcription factor
YY1 participates in many aspects of cell regulation including activa-
tion, repression, and modification of growth, development, and differ-
entiation GEPs [23]. DNA polδ participates in DNA replication and
DNA repair processes including base pair excision, nucleotide exci-
sion, and mismatch repair [24]. p53 protects the genomic integrity
by participating in cell cycle arrest, DNA repair, and apoptosis, and
it has been found to be overexpressed in hepatocellular carcinoma
[25]. After validating the GEPs, we observed that p38 expression, a
mitogen-activated protein kinase, was diminished with DEN treat-
ment and was not restored by CAPE [26]. The expression of p53, tran-
scription factor YY1, and DNA polδ was increased by DEN treat
ment, suggesting altered DNA repair and replication. Up-regulation
of these genes was avoided by CAPE pretreatment. After DEN bioac-
tivation, DNA damage is followed by DNA repair and replication;
however, if DEN is not completely metabolized, the DNA damage
is decreased. These effects are likely mediated directly by CAPE, with
subsequently reduced expression of YY1 and p53; the transcription
factor YY1 regulates the transcription of p53 [23]. Further investiga-
tion is required to determine the participation of these genes and their
protein products during carcinogenesis initiation.
There are many more genes that could be selected for further anal-
ysis from our microarray; thus, our analysis only represents an initial
effort to identify the genes participating in the initiation stage of this
model of chemical hepatocarcinogenesis.
Other groups of genes relevant for future validation and investiga-
tion include those encoding heat shock proteins, which are molecular
chaperones induced by several pathological stimuli. Alterations in
processing proteins have been related to the carcinogenesis process;
these proteins have been found to be overexpressed in gastric cancer,
and they serve as possible markers of tumorigenesis, malignant phe-
notype, tumor immunity, resistance to apoptosis, and poor prognosis
[27]. Several CYP family members seemed to be downregulated after
DEN administration; these include 3A1 and 2C11, which have been
previously reported to be downregulated most likely as the result of tis-
sue damage produced by DEN [28]. CYP down-regulation is expected
in the response to inflammation and infection. As consequence of gen-
eralized necrosis observed at 24 hours after DEN, the inflammation
may have contributed to CYP down-regulation, as previously reported
for CYP isoforms such as 2C11, 3A2, and 2E1 [29,30]. In addition,
several microglobulins and macroglobulins were downregulated, spe-
cifically α-2μ-globulins that might be involved in increased DEN-
mediated proliferation as previously reported [31].
Figure 5. RT-PCR validation of YY1, DNA polδ, p53, and p38 gene expression levels. Samples were analyzed by RT-PCR using primers
from Table 1. CAPE indicates rats killed 12 hours after CAPE dosing; D + C24, killed 24 hours after DEN dosing with CAPE pretreatment
12 hours before DEN (n = 4 in each group); D24, killed 24 hours after DEN dosing; NT, untreated. *P < .05 compared with NT, **P < .05
compared with D24 by Student’s t test.
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When CAPE was administered alone, it did not modify gene ex-
pression; but when DEN was administered after CAPE, a dramatic
response was obtained when compared with that produced by the
carcinogen alone. This induction of a protective phenotype by CAPE
is similar to a previously observed differentiation of effects between
normal and altered cells, where CAPE produced radiosensitization in
lung cancer [12], CT26 colorectal adenocarcinoma cells [13], and
preferential cytotoxicity in several cancer cells but not in normal ones
[15]. This intriguing effect of CAPE should be further investigated.
It would seem that tumor initiation by DEN induces changes in
GEP. These changes probably influence protein modifications. CAPE
given before DEN interferes with DEN-mediated expression changes
in genes involved in DEN bioactivation, oxidative stress regulation,
DNA repair and replication, among others. The effect of CAPE on this
process can be used as a tool to suggest new mechanisms for DEN ini-
tiation process in the modified resistant hepatocyte model as well as to
uncover possible molecular targets for liver cancer chemoprotection.
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Table W1. Upregulated Genes by DEN Even with CAPE Pretreatment.
Gene Name Ratio
1 Zinc finger protein 5 (fragment). [Source: SPTREMBL; Acc: P97661] 2.116
2 Neuronal acetylcholine receptor protein, alpha-7 chain precursor. [Source: SWISSPROT; Acc: Q05941] 1.866
3 Rab6-interacting protein 2; rim-binding protein; ELKS. [Source: RefSeq; Acc: NM_170788] 1.772
4 40S ribosomal protein S5. [Source: SWISSPROT; Acc: P24050] 1.648
5 Zinc finger protein 10 (fragment). [Source: SPTREMBL; Acc: P97649] 1.994
6 Ring finger protein OIP1. [Source: RefSeq; Acc: NM_134467] 2.615
7 40S ribosomal protein SA (P40) (34/67 kDA laminin receptor). [Source: SWISSPROT; Acc: P38983] 1.778
8 DNA-directed RNA polymerase I 135 kDA polypeptide (EC 2.7.7.6) (RNA polymerase I subunit 2) (RPA135) (RNA polymerase I 127 kDA subunit). [Source: SWISSPROT;
Acc: O54888]
1.652
9 Cytochrome P450 27, mitochondrial precursor (EC 1.14.–.–) (cytochrome P-450C27/25) (sterol 26-hydroxylase) (sterol 27-hydroxylase) (vitamin D(3) 25-hydroxylase)
(5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol 27-hydroxylase). [Source: SWISSPROT; Acc: P1717
1.584
10 60S ribosomal protein L13A. [Source: SWISSPROT; Acc: P35427] 1.862
11 Histamine H3 receptor (HH3R). [Source: SWISSPROT; Acc: Q9QYN8] 2.138
12 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/FRU-2,6-P2ASE brain-type isozyme) (RB2K) [includes: 6-phosphofructo-2-kinase
(EC 2.7.1.105); fructose-2,6-bisphosphatase (EC 3.1.3.46)]. [Source: SWISSPROT; Acc: O35552]
1.784
13 Chymotrypsinogen B precursor (EC 3.4.21.1). [Source: SWISSPROT; Acc: P07338] 2.284
14 UDP-glucose 4-epimerase (EC 5.1.3.2) (galactowaldenase) (UDP-galactose 4-epimerase). [Source: SWISSPROT; Acc: P18645] 1.659
15 Zinc finger protein OZF (POZF-1). [Source: SWISSPROT; Acc: Q62981] 2.059
16 Epoxide hydrolase 1 (EC 3.3.2.3) (microsomal epoxide hydrolase) (epoxide hydratase). [Source: SWISSPROT; Acc: P07687] 2.329
17 60S ribosomal protein L35A. [Source: SWISSPROT; Acc: P04646] 1.647
18 40S ribosomal protein S17. [Source: SWISSPROT; Acc: P04644] 1.813
19 60S acidic ribosomal protein P2. [Source: SWISSPROT; Acc: P02401] 2.007
20 Eosinophil granule major basic protein precursor (MBP). [Source: SWISSPROT; Acc: Q63189] 1.657
21 Zinc finger protein 5 (fragment). [Source: SPTREMBL; Acc: P97644] 2.412
22 Dynein-like protein 10 (fragment). [Source: SPTREMBL; Acc: Q63161] 1.999
23 60S ribosomal protein L9. [Source: SWISSPROT; Acc: P17077] 1.711
24 HMGIC fusion partner-like protein 4. [Source: RefSeq; Acc: NM_181387] 1.622
25 Brain-enriched SH3-domain protein (BESH3). [Source: RefSeq; Acc: NM_139334] 1.678
26 ATP-binding cassette, subfamily C (CFTR/MRP), member 3. [Source: RefSeq; Acc: NM_080581] 2.251
27 ELAC homolog 2. [Source: RefSeq; Acc: NM_172326] 1.512
28 ER transmembrane protein DRI 42. [Source: RefSeq; Acc: NM_138905] 2.282
29 Cathepsin L precursor (EC 3.4.22.15) (major excreted protein) (MEP) (cyclic protein-2) (CP-2). [Source: SWISSPROT; Acc: P07154] 2.346
30 60S ribosomal protein L18. [Source: SWISSPROT; Acc: P12001] 1.861
31 Glyceraldehyde 3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) (38 kDA BFA-dependent aDP-ribosylation substrate) (BARS-38). [Source: SWISSPROT; Acc: P04797] 1.554
32 High mobility group protein 2 (HMG-2). [Source: SWISSPROT; Acc: P52925] 2.395
33 40S ribosomal protein S27. [Source: SWISSPROT; Acc: P24051] 1.843
34 A-Kinase anchor protein 8 (A-kinase anchor protein 95 kDA) (AKAP 95). [Source: SWISSPROT; Acc: Q63014] 1.605
35 Parathyroid hormone receptor precursor (PTH2 receptor).[Source: SWISSPROT; Acc: P70555] 2.140
36 ARF GTPase-activating protein GIT1 (G protein-coupled receptor kinase-interactor 1). [Source: SWISSPROT; Acc: Q9Z272] 1.710
37 Gastrin precursor. [Source: SWISSPROT; Acc: P04563] 1.743
38 Taste receptor type 2 member 23 (T2R23) (taste receptor type 2 member 2) (T2R2). [Source: SWISSPROT; Acc: Q9JKF0] 2.103
39 Cell division cycle 5-like; CDC5 (cell division cycle 5, Schizosaccharomyces pombe, homolog)-like. [Source: RefSeq; Acc: NM_053527] 1.538
40 Solute carrier family 21 member 2 (prostaglandin transporter) (PGT) (matrin F/G). [Source: SWISSPROT; Acc: Q00910] 1.553
41 Peripheral plasma membrane protein CASK (EC 2.7.1.–) (calcium/calmodulin–dependent serine protein kinase). [Source: SWISSPROT; Acc: Q62915] 2.207
42 Zinc finger protein 16 (fragment). [Source: SPTREMBL; Acc: P97672] 1.923
43 40S ribosomal protein S21. [Source: SWISSPROT; Acc: P05765] 1.620
44 L-Lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A) (LDH muscle subunit) (LDH-M). [Source: SWISSPROT; Acc: P04642] 1.524
45 Peroxisome proliferator–activated receptor gamma coactivator 1β-2A. [Source: RefSeq; Acc: NM_176075] 2.008
46 Stromelysin-1 precursor (EC 3.4.24.17) (matrix metalloproteinase-3) (MMP-3) (TRANSIN-1) (SL-1) (PTR1 protein). [Source: SWISSPROT; Acc: P03957] 1.591
47 Ornithine decarboxylase (EC 4.1.1.17) (ODC). [Source: SWISSPROT; Acc: P09057] 1.781
48 Prolactin regulatory element-binding protein. 1.726
49 Linker for activation of T cells (36 kDA phospho-tyrosine adaptor protein) (PP36) (P36-38). [Source: SWISSPROT; Acc: O70601] 1.965
50 Protein kinase LYK5. [Source: RefSeq; Acc: NM_182820] 1.639
51 Gonadotropin-inducible ovarian transcription factor 2. [Source: RefSeq; Acc: NM_133390] 1.868
52 Tripeptidyl-peptidase II (EC 3.4.14.10) (TPP-II) (tripeptidyl aminopeptidase) (cholecystokinin-inactivating peptidase). [Source: SWISSPROT; Acc: Q64560] 1.906
53 Osteomodulin precursor (osteoadherin) (OSAD) (keratan sulfate proteoglycan osteomodulin) (KSPG osteomodulin). [Source: SWISSPROT; Acc: Q9Z1S7] 1.801
54 Tropomyosin isoform 6. [Source: RefSeq; Acc: NM_173111] 1.796
55 Heat shock protein HSP 90-beta (HSP 84). [Source: SWISSPROT; Acc: P34058] 1.992
56 Chemokine (C-C) receptor 4. [Source: RefSeq; Acc: NM_133532] 1.502
57 Class I MHC heavy chain RT1.A(N) antigen precursor. [Source: SPTREMBL; Acc: P79588] 1.674
58 Max interacting protein 1 (MXI1 protein). [Source: SWISSPROT; Acc: O09015] 1.718
59 BMP/retinoic acid–inducible neural-specific protein 3. [Source: RefSeq; Acc: NM_173121] 1.641
60 Prothymosin α. [Source: SWISSPROT; Acc: P06302] 1.840
61 Cadherin-4 (retinal-cadherin) (R-cadherin) (R-CAD) (fragment). [Source: SWISSPROT; Acc: Q63149] 2.415
62 Bone morphogenetic protein 1 (fragment). [Source: SPTREMBL; Acc: Q91WZ0] 1.653
63 Vitamin D–dependent calcium-binding protein, intestinal (CABP) (calbindin D9K) (cholecalcin). [Source: SWISSPROT; Acc: P02634] 1.573
64 Hormone-sensitive lipase (EC 3.1.1.–) (HSL). [Source: SWISSPROT; Acc: P15304] 1.698
65 Metastasis-associated protein MTA1. [Source: SWISSPROT; Acc: Q62599] 1.545
66 Obscurin (fragment). [Source: SPTREMBL; Acc: Q80ZF5] 1.737
This list was selected with Bioplot (Web site of Biopuce) upregulated threshold = 1.5, P < .05.
Table W2. Upregulated Genes by DEN Restored to Profile Level of Non Treated Rats with CAPE Pretreatment.
Gene Name Ratio
1 Zinc finger protein 37 (ZFP-37). [Source: SWISSPROT; Acc: O88553] 1.760
2 Zinc finger protein 1 (fragment). [Source: SPTREMBL; Acc: P97657] 1.926
3 Serologically defined breast cancer antigen NY-BR-16-like protein (fragment). [Source: SPTREMBL; Acc: Q99MD2] 1.636
4 Amiloride-sensitive sodium channel gamma-subunit (epithelial Na+ channel gamma subunit) (gamma ENAC) (non–voltage-gated sodium channel 1 gamma subunit) (SCNEG)
(gamma NACH). [Source: SWISSPROT; Acc: P37091]
1.538
5 Cytochrome b-245 light chain (P22 phagocyte B-cytochrome) (neutrophil cytochrome b, 22 kDA polypeptide) (P22-PHOX) (cytochrome B(558) alpha chain) (cytochrome b558
alpha-subunit) (superoxide-generating NADPH oxidase light chain subunit). [Source: SWISSPROT; Acc: Q61462]
1.592
6 Copper transport protein ATOX1 (metal transport protein ATX1). [Source: SWISSPROT; Acc: Q9WUC4] 1.509
7 Kinesin-related protein 3A (fragment). [Source: SPTREMBL; Acc: O54720] 1.568
8 Cathepsin R. [Source: RefSeq; Acc: NM_175581] 1.595
9 CCAAT-binding transcription factor subunit B (CBF-B) (NF-Y protein chain A) (NF-YA) (CAAT-Box DNA binding protein subunit A). [Source: SWISSPROT; Acc: P18576] 1.589
10 Splicing factor 1 homolog (fragment). 1.524
11 60S ribosomal protein L26. [Source: SWISSPROT; Acc: P12749] 1.533
12 Transcription factor MTSG1. [Source: RefSeq; Acc: NM_178093] 1.567
13 Potassium voltage-gated channel subfamily G member (potassium channel KV6.3) (KV10.1). [Source: SWISSPROT; Acc: Q8R523] 1.606
14 Disrupted in schizophrenia 1. [Source: RefSeq; Acc: NM_175596] 1.515
15 Pius protein. [Source: RefSeq; Acc: NM_021660] 1.562
16 Cytochrome c oxidase polypeptide VIIA-liver/heart, mitochondrial precursor (EC 1.9.3.1) (cytochrome c oxidase subunit VIIA-L). [Source: SWISSPROT; Acc: P35171] 1.534
17 Neuronal tropomodulin (N-TMOD) (tropomodulin 2). [Source: SWISSPROT; Acc: P70566] 1.713
18 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor (EC 5.3.3.8) (dodecenoyl-CoA delta-isomerase). [Source: SWISSPROT; Acc: P23965] 1.605
19 60S ribosomal protein L12. [Source: SWISSPROT; Acc: P23358] 1.502
20 Prokineticin 2 precursor (PK2). [Source: SWISSPROT; Acc: Q8R413] 1.511
21 Troponin T1, skeletal, slow. [Source: RefSeq; Acc: NM_134388] 1.516
23 Chloride channel protein, skeletal muscle (chloride channel protein 1) (CLC-1). [Source: SWISSPROT; Acc: P35524] 1.697
24 Neuroendocrine convertase 2 precursor (EC 3.4.21.94) (NEC 2) (PC2) (prohormone convertase 2) (proprotein convertase 2) (KEX2-like endoprotease 2). [Source: SWISSPROT;
Acc: P28841]
1.621
25 Glutathione S -transferase, mitochondrial (EC 2.5.1.18) (GST 13-13) (glutathione S -transferase subunit 13) (GST class-kappa). [Source: SWISSPROT; Acc: P24473] 1.530
This list was selected with Bioplot (Web site of Biopuce) upregulated threshold = 1.5, P < .05 with Student’s t test.
Table W3. Upregulated Genes Only When There Is CAPE Pretreatment before DEN.
Gene Name Ratio
1 Prominin; fudenine. [Source: RefSeq; Acc: NM_021751] 1.537
2 β Platelet-derived growth factor receptor precursor (EC 2.7.1.112) (PDGF-R-BETA). [Source: SWISSPROT; Acc: Q05030] 1.564
3 Glutathione reductasE. [Source: RefSeq; Acc: NM_053906] 1.536
4 Cathepsin M. [Source: RefSeq; Acc: NM_181378] 1.649
5 Acetylcholine receptor protein, epsilon chain precursor. [Source: SWISSPROT; Acc: P09660] 1.535
6 Fibrinogen gamma chain precursor. [Source: SWISSPROT; Acc: P02680] 1.766
7 Protein-tyrosine phosphatase, non-receptor type 1 (EC 3.1.3.48) (protein-tyrosine phosphatase 1b) (PTP-1B). [Source: SWISSPROT; Acc: P20417] 1.530
8 Thyroglobulin precursor. [Source: SWISSPROT; Acc: P06882] 1.700
9 Deformed epidermal autoregulatory factor 1 homolog (nuclear DEAF-1–related transcriptional regulator) (NUDR) (suppressin). [Source: SWISSPROT; Acc: O88450] 1.501
10 C-CAM4 protein. [Source: RefSeq; Acc: NM_173339] 1.653
11 Glutamate receptor, ionotropic kainate 2 precursor (glutamate receptor 6) (GLUR-6) (GLUR6). [Source: SWISSPROT; Acc: P42260] 2.195
12 Syndecan-4 precursor (ryudocan core protein). [Source: SWISSPROT; Acc: P34901] 1.561
13 Insulin receptor–related protein precursor (EC 2.7.1.112) (IRR) (IR-related receptor) (fragments). [Source: SWISSPROT; Acc: Q64716] 1.781
14 BM1N (fragment). [Source: SPTREMBL; Acc: Q9QUQ2] 1.623
15 Hepcidin precursor. [Source: SWISSPROT; Acc: Q99MH3] 1.762
16 GTP cyclohydrolase I precursor (EC 3.5.4.16) (GTP-CH-I). [Source: SWISSPROT; Acc: P22288] 1.527
17 Protein-glutamine glutamyltransferase 4 (EC 2.3.2.13) (TGASE 4) (dorsal prostate transglutaminase) (dorsal protein 1) (DP1). [Source: SWISSPROT; Acc: Q99041] 1.746
18 Hepatoma-derived growth factor. 1.770
19 Oligodendrocyte transcription factor 1 (OLIGO1) (OLG-1 BHLH protein). [Source: SWISSPROT; Acc: Q9WUQ3] 1.624
20 Growth hormone receptor precursor (GH RECEPTOR) (serum binding protein). [Source: SWISSPROT; Acc: P16310] 1.522
21 Inward rectifier potassium channel 2 (potassium channel, inwardly rectifying, subfamily J, member 2) (inward rectifier K+ channel KIR2.1) (RBL-IRK1). [Source: SWISSPROT;
Acc: Q64273]
1.629
22 Myosin IXA. [Source: RefSeq; Acc: NM_134335] 1.550
23 Paired basic amino acid cleaving enzyme 4 precursor (EC 3.4.21.–) (subtilisin/kexin-like). 1.501
24 Fuctinin 1 (fucosyltransferase inhibitor 1) (fragment). [Source: SWISSPROT; Acc: P80347] 1.547
25 Stromelysin-1 precursor (EC 3.4.24.17) (matrix metalloproteinase-3) (MMP-3) (TRANSIN-1) (SL-1) (PTR1 protein). [Source: SWISSPROT; Acc: P03957] 1.509
26 P105 coactivator. [Source: RefSeq; Acc: NM_022694] 1.752
27 TEC kinase (fragment). [Source: SPTREMBL; Acc: Q9EQ78] 1.590
28 Down syndrome critical region gene 1. [Source: RefSeq; Acc: NM_153724] 1.542
29 Ryanodine receptor type 1 (fragment). [Source: SPTREMBL; Acc: Q9R1G1] 1.674
30 Ring finger protein momo (fragment). [Source: SPTREMBL; Acc: Q8CIP0] 1.689
31 Dual-specificity protein phosphatase 6 (EC 3.1.3.48) (EC 3.1.3.16) (mitogen-activated protein kinase phosphatase 3) (MAP kinase phosphatase 3) (MKP-3).
[Source: SWISSPROT; Acc: Q64346]
1.737
32 Tripartite motif protein 17; ring finger protein TERF. [Source: RefSeq; Acc: NM_022798] 1.619
33 Nuclear pore complex protein NUP88 (nucleoporin NUP88) (88 kDA nuclear pore complex protein) (nucleoporin NUP84). [Source: SWISSPROT; Acc: O08658] 1.515
34 Cytohesin 2 (ARF nucleotide-binding site opener) (ARNO protein) (CLM2) (SEC7 homolog B) (MSEC7-2). [Source: SWISSPROT; Acc: P97695] 1.530
This list was selected with Bioplot (Web site of Biopuce) upregulated threshold = 1.5, P < .05 with Student’s t test.
Table W4. Downregulated Genes by DEN Continued Underexpressed Even with CAPE Pretreatment.
Gene Name Ratio
1 Cytochrome P450PB-1 (fragment). [Source: SPTREMBL; Acc: Q64614] 0.5942
2 Liver regeneration protein LRRYAN. [Source: RefSeq; Acc: NM_182474] 0.223
3 Adenosine kinase (EC 2.7.1.20) (AK) (adenosine 5′-phosphotransferase). [Source: SWISSPROT; Acc: Q64640] 0.635
4 Cytochrome P450 2C6 (EC 1.14.14.1) (CYPIIC6) (P450 PB1) (PTF2). [Source: SWISSPROT; Acc: P05178] 0.482
5 Cytochrome P450 2C24 (EC 1.14.14.1) (CYPIIC24) (P450-PROS2) (FRAGMENT). [Source: SWISSPROT; Acc: P33273] 0.499
6 Adenosylhomocysteinase (EC 3.3.1.1) (S -adenosyl-L-homocysteine hydrolase) (ADOHCYASE). [Source: SWISSPROT; Acc: P10760] 0.611
7 Cytochrome P450 2J3 (EC 1.14.14.1) (CYPIIJ3). [Source: SWISSPROT; Acc: P51590] 0.515
8 Meprin A α-subunit precursor (EC 3.4.24.18) (endopeptidase-2) (MEP-1) (endopeptidase-24.18 α-subunit) (E-24.18). [Source: SWISSPROT; Acc: Q64230] 0.654
9 G protein–coupled receptor 64. [Source: RefSeq; Acc: NM_181366] 0.592
10 α-2U globulin PGCL4. [Source: RefSeq; Acc: NM_147215] 0.443
11 Dihydropyridine-sensitive L-type, calcium channel β-1 subunit (CAB1) (voltage-dependent calcium channel β-1 subunit). [Source: SWISSPROT; Acc: P54283] 0.524
12 PAM COOH-terminal interactor protein 1. [Source: RefSeq; Acc: NM_022959] 0.456
13 ATP synthase oligomycin sensitivity conferral protein, mitochondrial precursor (EC 3.6.3.14) (OSCP). [Source: SWISSPROT; Acc: Q06647] 0.516
14 Major urinary protein precursor (MUP) (α-2U-globulin) (15.5 kDA fatty acid binding protein) (15.5 kDA FABP) (alpha(2)-euglobulin) (allergen RAT N 1) (RAT N I).
[Source: SWISSPROT; Acc: P02761]
0.514
15 Mammary cancer–associated protein RMT-1. [Source: RefSeq; Acc: NM_145088] 0.539
16 α-2U globulin PGCL5. [Source: RefSeq; Acc: NM_147213] 0.531
17 Hexaprenyldihydroxybenzoate methyltransferase, mitochondrial precursor (EC 2.1.1.114) (dihydroxyhexaprenylbenzoate methyltransferase) (3,4-dihydroxy-5-hexaprenylbenzoate
methyltransferase) (DHHB methyltransferase) (DHHB-MT) (DHHB-MTASE). [Source: SWISSPRO
0.658
18 Lysophospholipase 1. [Source: RefSeq; Acc: NM_013006] 0.620
19 α-2U globulin. [Source: SPTREMBL; Acc: Q63221] 0.590
20 FAM3C-like protein. [Source: SPTREMBL; Acc: Q810F4] 0.609
21 Retinoblastoma-binding protein 9 (RBBP-9) (B5T overexpressed gene protein) (BOG protein). [Source: SWISSPROT; Acc: O88350] 0.442
22 Neuronal differentiation–related gene. [Source: RefSeq; Acc: NM_139333] 0.485
23 Calgranulin B (migration inhibitory factor–related protein 14) (MRP-14) (P14). [Source: SWISSPROT; Acc: P50116] 0.559
24 Cytochrome P450 2D2 (EC 1.14.14.1) (CYPIID2) (P450-DB2) (P450-CMF2) (debrisoquine 4-hydroxylase). [Source: SWISSPROT; Acc: P10634] 0.661
25 Adenomatous polyposis coli protein (APC protein). [Source: SWISSPROT; Acc: P70478] 0.431
26 CC chemokine CCL28. [Source: RefSeq; Acc: NM_053700] 0.635
27 Nuclear RNA export factor 1 (TIP associating protein) (TIP-associated protein) (mRNA export factor TAP). [Source: SWISSPROT; Acc: O88984] 0.598
28 Flavohemoprotein B5 + B5R. [Source: RefSeq; Acc: NM_133427] 0.625
29 Cytochrome P450 2C11 (EC 1.14.14.1) (CYPIIC11) (P-450(M-1)) (P450H) (P450-UT-A) (UT-2). [Source: SWISSPROT; Acc: P08683] 0.610
30 Vascular endothelial growth factor receptor 1 precursor (EC 2.7.1.112) (VEGFR-1) (tyrosine-protein kinase receptor FLT) (FLT-1). [Source: SWISSPROT; Acc: P53767] 0.587
31 cytochrome P450 3A1 (EC 1.14.14.1) (CYPIIIA1) (P450-PCN1). [Source: SWISSPROT; Acc: P04800] 0.527
32 Testis-specific transporter TST-2. [Source: RefSeq; Acc: NM_173338] 0.665
33 α 2U-globulin (fragment). [Source: SPTREMBL; Acc: Q63220] 0.522
34 Ubiqutin carboxyl-terminal hydrolase L3. [Source: SPTREMBL; Acc: Q91Y78] 0.592
35 3-OXO-5-beta-steroid 4-dehydrogenase (EC 1.3.99.6) (delta(4)-3-ketosteroid 5-beta-reductase) (aldo-keto reductase family 1 member D1). [Source: SWISSPROT; Acc: P31210] 0.625
36 Serotransferrin precursor (transferrin) (siderophilin) (β-1–metal binding globulin). [Source: SWISSPROT; Acc: P12346] 0.445
37 RPB17 protein (fragment). [Source: SPTREMBL; Acc: Q9Z0W2] 0.596
38 GTP-binding protein RAB0. [Source: RefSeq; Acc: NM_145094] 0.562
39 Protein tyrosine phosphatase epsilon M precursor (fragment). [Source: SPTREMBL; Acc: Q63476] 0.638
40 Serum albumin precursor [contains: neurotensin-related peptide (NRP)]. [Source: SWISSPROT; Acc: P02770] 0.412
41 Sodium- and chloride-dependent GABA transporter 3. [Source: SWISSPROT; Acc: P31647] 0.551
42 Membrane protein, palmitoylated 4 (MAGUK P55 subfamily member 4). [Source: RefSeq; Acc: NM_021265] 0.599
43 Cortexin. [Source: SWISSPROT; Acc: P41237] 0.645
44 MAP-Kinase activating death domain; RAB3 GDP/GTP exchange protein. [Source: RefSeq; Acc: NM_053585] 0.645
45 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1. [Source: RefSeq; Acc: NM_053523] 0.407
46 Adrenal secretory serine protease precursor. [Source: RefSeq; Acc: NM_022630] 0.613
47 Mothers against decapentaplegic homolog 1 (SMAD 1) (mothers against DPP homolog 1). [Source: SWISSPROT; Acc: P97588] 0.527
48 Cytochrome P450 2C22 (EC 1.14.14.1) (CYPIIC22) (P450 MD) (P450 P49). [Source: SWISSPROT; Acc: P19225] 0.612
49 CD80 antigen CD80 a rat homolog of the human D28/CTLA-4 ligand (B7-1). [Source: RefSeq; Acc: NM_012926] 0.615
50 RPB17 protein (fragment). [Source: SPTREMBL; Acc: Q9Z0W2] 0.615
51 Inter–α-trypsin inhibitor heavy chain H3 precursor (ITI heavy chain H3) (inter–α-inhibitor heavy chain 3). [Source: SWISSPROT; Acc: Q63416] 0.579
52 Sodium/potassium–transporting ATPase α-4 chain (EC 3.6.3.9) (sodium pump 4) (Na+/K+ ATPase 4). [Source: SWISSPROT; Acc: Q64541 0.607
53 Phospholipid scramblase 1 (PL scramblase 1) (Ca(2+)-dependent phospholipid scramblase 1). [Source: SWISSPROT; Acc: P58195] 0.547
54 Cytochrome P450 2C12, female-specific (EC 1.14.14.1) (CYPIIC12) (P450I) (15-BETA) (P450-UT-I) (UT-1). [Source: SWISSPROT; Acc: P11510] 0.571
55 Mast cell protease I precursor (EC 3.4.21.39) (RMCP-I) (RMCP-1) (CHYMASE). [Source: SWISSPROT; Acc: P09650] 0.488
56 Vav proto-oncogene (P95). [Source: SWISSPROT; Acc: P54100] 0.635
This list was selected with Bioplot (Web site of Biopuce) downregulated threshold = 0.66, P < .05 with Student’s t test.
Table W5. Downregulated Genes by DEN Restored to Profile Level of Non Treated Rats with CAPE Pretreatment.
Gene Name Ratio
1 Cytochrome B5. [Source: SWISSPROT; Acc: P00173] 0.633
2 Cytochrome P450 3A18 (EC 1.14.14.1) (CYPIIIA18) (P450(6)beta-2). [Source: SWISSPROT; Acc: Q64581] 0.618
3 Hydroxymethylglutaryl-CoA synthase, mitochondrial precursor (EC 2.3.3.10) (HMG-CoA synthase) (3-hydroxy-3-methylglutaryl coenzyme A synthase). [Source: SWISSPROT;
Acc: P22791]
0.647
4 Acyl-CoA desaturase (EC 1.14.19.1) (stearoyl-CoA desaturase) (fatty acid desaturase) (delta(9)-desaturase). [Source: SWISSPROT; Acc: P07308] 0.657
5 Vesicular glutamate transporter 3. [Source: RefSeq; Acc: NM_153725] 0.620
6 Cytochrome P450 2C13, male-specific (EC 1.14.14.1) (CYPIIC13) (P450-G) (UT-5). [Source: SWISSPROT; Acc: P20814] 0.660
7 Putative RNA binding protein 1 (fragment). [Source: SPTREMBL; Acc: O08882] 0.646
8 Cyclin-dependent kinase inhibitor 2A (P16, INHIBITS CDK4). [Source: RefSeq; Acc: NM_031550] 0.662
9 Phosphorylase B kinase gamma catalytic chain, testis/liver isoform (EC 2.7.1.38) (PHK-GAMMA-T) (phosphorylase kinase gamma subunit 2). [Source: SWISSPROT; Acc: P31325] 0.661
10 Carbonic anhydrase III (EC 4.2.1.1) (carbonate dehydratase III) (CA-III). [Source: SWISSPROT; Acc: P14141] 0.658
11 α-2-Macroglobulin precursor (α-2-M). [Source: SWISSPROT; Acc: P06238] 0.641
12 Anion exchange protein 2 (non-erythroid band 3-like protein) (B3RP). [Source: SWISSPROT; Acc: P23347] 0.655
13 Calpain 8. [Source: RefSeq; Acc: NM_133309] 0.655
This list was selected with Bioplot (Web site of Biopuce) downregulated threshold = 0.66, P < .05 with Student’s t test.
Table W6. Downregulated Genes Only When There Is CAPE Pretreatment before DEN.
Gene Name Ratio
1 Cytochrome P450, 1A2; cytochrome P450, subfamily I (aromatic compound-inducible), member A2 (Q42, FORM D). [Source: RefSeq; Acc: NM_012541] 0.577
2 Proton-associated sugar transporter A. [Source: RefSeq; Acc: NM_144747] 0.560
3 MHC class I protein precursor. [Source: SPTREMBL; Acc: Q9JHM2] 0.599
4 Ferritin light chain (ferritin L subunit). [Source: SWISSPROT; Acc: P02793] 0.592
5 Pregnancy-zone protein. [Source: RefSeq; Acc: NM_145779] 0.591
6 Excitatory amino acid transporter 3 (sodium-dependent glutamate/aspartate transporter 3) (excitatory amino acid carrier 1). [Source: SWISSPROT; Acc: P51907] 0.478
7 Indoleamine 2,3-dioxygenase. [Source: RefSeq; Acc: NM_023973] 0.583
8 BM1N (fragment). [Source: SPTREMBL; Acc: Q9QUQ2] 0.492
9 Diacylglycerol kinase, beta (EC 2.7.1.107) (diglyceride kinase) (DGK-BETA) (DAG kinase beta) (90 kDA diacylglycerol kinase). [Source: SWISSPROT; Acc: P49621] 0.656
10 Vitamin D–binding protein precursor (DBP) (group-specific component) (GC-globulin) (VDB). [Source: SWISSPROT; Acc: P04276] 0.608
11 Period homolog 3. [Source: RefSeq; Acc: NM_023978] 0.618
12 Leucine-rich glioma-inactivated protein 1 precursor. [Source: SWISSPROT; Acc: Q8K4Y5] 0.659
13 MSX-interacting-zinc finger. [Source: RefSeq; Acc: NM_053337] 0.426
14 Clock gene. [Source: RefSeq; Acc: NM_021856] 0.460
15 Sodium-dependent neutral amino acid transporter ASCT2. [Source: RefSeq; Acc: NM_175758] 0.607
16 NK cell lectin-like receptor family E, member 1. [Source: RefSeq; Acc: NM_181372] 0.617
17 DREBRIN (developmentally regulated brain protein). [Source: SWISSPROT; Acc: Q07266] 0.472
18 Sperm autoantigenic protein 17. [Source: RefSeq; Acc: NM_053482] 0.576
19 Leucine-rich repeat-containing protein 15 precursor (RLIB). [Source: SWISSPROT; Acc: Q8R5M3] 0.533
20 Lamin A. [Source: SWISSPROT; Acc: P48679] 0.524
21 Galactoside 2-α-L-fucosyltransferase 2 (EC 2.4.1.69) (secretor blood group α-2-fucosyltransferase) (GDP-L-fucose:β-D-galactoside 2-alpha-L-fucosyltransferase 2) (α(1,2)FT 2)
(fucosyltransferase 2) (fragment). [Source: SWISSPROT; Acc: Q10984]
0.569
22 RN protein. [Source: RefSeq; Acc: NM_133585] 0.551
23 Mitogen-activated protein kinase 14 (EC 2.7.1.37) (mitogen-activated protein kinase p38α) (MAP kinase p38α). [Source: SWISSPROT; Acc: P70618] 0.631
24 Trypsin III, cationic precursor (EC 3.4.21.4) (pretrypsinogen III). [Source: SWISSPROT; Acc: P08426] 0.341
25 Glycogenin-1 (EC 2.4.1.186). [Source: SWISSPROT; Acc: O08730] 0.551
26 Transcription termination factor, mitochondrial. [Source: RefSeq; Acc: NM_053499] 0.644
27 Tyrosine-protein kinase CSK (EC 2.7.1.112) (C-SRC kinase). [Source: SWISSPROT; Acc: P32577] 0.518
28 Neurturin. [Source: SPTREMBL; Acc: Q811Q5] 0.524
29 Cellular tumor antigen p53 (tumor suppressor p53). [Source: SWISSPROT; Acc: P10361] 0.509
30 Partitioning-defective 3 homolog (PARD-3) (PAR-3) (atypical PKC isotype-specific interacting protein) (ASIP) (atypical PKC specific binding protein) (ASBP).
[Source: SWISSPROT; Acc: Q9Z340]
0.655
31 Small inducible cytokine A5 precursor (CCL5) (T-cell–specific rantes protein) (SIS-delta). [Source: SWISSPROT; Acc: P50231] 0.568
32 CDIG1L protein. [Source: RefSeq; Acc: NM_153623] 0.644
33 RT1 class IB gene, H2-TL-like, GRC region. [Source: RefSeq; Acc: NM_012646] 0.601
34 Alcohol sulfotransferase A (EC 2.8.2.2) (hydroxysteroid sulfotransferase A) (STA) (androsterone-sulfating sulfotransferase) (AD-ST) (ST-40). [Source: SWISSPROT; Acc: P22789] 0.615
35 RHO-interacting protein 3 (P116RIP) (RIP3). [Source: SWISSPROT; Acc: Q9ERE6] 0.569
36 Heat shock protein, β-2 (HSPB2). [Source: SWISSPROT; Acc: O35878] 0.650
37 Transcription factor SOX-10. [Source: SWISSPROT; Acc: O55170] 0.529
38 Cation chloride cotransporter 9. [Source: RefSeq; Acc: NM_153625] 0.665
39 N -ethylmaleimide–sensitive factor. [Source: RefSeq; Acc: NM_021748] 0.472
40 Cytochrome c oxidase subunit IV isoform 2, mitochondrial precursor (EC 1.9.3.1) (COX IV-2). [Source: SWISSPROT; Acc: Q91Y94] 0.646
41 Serotonin N -acetyltransferase (EC 2.3.1.87) (aralkylamine N -acetyltransferase) (AA-NAT) (serotonin acetylase). [Source: SWISSPROT; Acc: Q64666] 0.582
42 Sterol O-acyltransferase 1 (EC 2.3.1.26) (cholesterol acyltransferase 1) (acyl coenzyme A:cholesterol acyltransferase 1) (ACAT-1). [Source: SWISSPROT; Acc: O70536] 0.593
43 Calcium-activated potassium channel β2. [Source: RefSeq; Acc: NM_176861] 0.479
44 Outer dense fiber protein (RT7 protein) (RTS 5/1). [Source: SWISSPROT; Acc: P21769] 0.602
45 Contrapsin-like protease inhibitor 1 precursor (CPI-21) (kallikrein-binding protein) (KBP) (growth hormone–regulated proteinase inhibitor) (serine protease inhibitor 2) (SPI-2)
(GHR-P63) (SPI-2.3) (thyroid hormone–regulated protein). [Source: SWISSPROT; Acc: P05545]
0.655
46 Biglycan precursor (bone/cartilage proteoglycan I) (PG-S1). [Source: SWISSPROT; Acc: P47853] 0.519
47 Doublesex and MAB-3 related transcription factor 1. [Source: RefSeq; Acc: NM_053706] 0.580
48 Fatty acid–binding protein, brain (B-FABP) (brain lipid-binding protein) (BLBP). [Source: SWISSPROT; Acc: P55051] 0.487
49 von Willebrand factor vWF (von Willibrand factor) (fragment). [Source: SPTREMBL; Acc: Q62935] 0.656
50 Maspin precursor (protease inhibitor 5). [Source: SWISSPROT; Acc: P70564] 0.629
51 Receptor-activity modifying protein 1. [Source: RefSeq; Acc: NM_031645] 0.654
52 Transketolase (EC 2.2.1.1) (TK). [Source: SWISSPROT; Acc: P50137] 0.581
53 Transcription factor E2F6 (fragment). [Source: SPTREMBL; Acc: Q80ZB0] 0.624
54 Golgi autoantigen, golgin subfamily A member 2 (cis-Golgi matrix protein GM130). [Source: SWISSPROT; Acc: Q62839] 0.630
55 Dynein-like protein 5 (fragment). [Source: SPTREMBL; Acc: Q63168] 0.614
56 DNA polymerase gamma subunit 1 (EC 2.7.7.7) (mitochondrial dna polymerase catalytic subunit) (POLG-alpha). [Source: SWISSPROT; Acc: Q9QYV8] 0.528
57 Keratinocyte growth factor precursor (KGF) (fibroblast growth factor-7) (FGF-7) (HBGF-7). [Source: SWISSPROT; Acc: Q02195] 0.559
58 ferm-domain-containing protein 163SCII (fragment). [Source: SPTREMBL; Acc: Q8VII0] 0.662
59 Titin (fragment). [Source: SPTREMBL; Acc: Q9JJ49] 0.618
60 Carbonic anhydrase IV precursor (EC 4.2.1.1) (carbonate dehydratase IV) (CA-IV). [Source: SWISSPROT; Acc: P48284] 0.635
61 DNA polymerase delta catalytic subunit (EC 2.7.7.7). [Source: SWISSPROT; Acc: O54747] 0.627
62 Serine/threonine-protein kinase PAK 3 (EC 2.7.1.–) (P21-activated kinase 3) (PAK-3) (beta-PAK) (P65-PAK). [Source: SWISSPROT; Acc: Q62829] 0.586
63 Noggin precursor (fragment). [Source: SWISSPROT; Acc: Q62809] 0.663
64 Sphingosine kinase 1. [Source: RefSeq; Acc: NM_133386] 0.586
65 Tyrosine 3-monooxygenase (EC 1.14.16.2) (tyrosine 3-hydroxylase) (TH). [Source: SWISSPROT; Acc: P04177] 0.662
66 Protein kinase C, epsilon type (EC 2.7.1.–) (NPKC-epsilon). [Source: SWISSPROT; Acc: P09216] 0.626
67 Retinal pigment epithelium, 65 kDA. [Source: RefSeq; Acc: NM_053562] 0.554
68 Cytochrome c oxidase polypeptide via - heart, mitochondrial precursor (EC 1.9.3.1) (COXVIAH) (fragment). [Source: SWISSPROT; Acc: P10817] 0.595
69 β-Arrestin 1 (arrestin, beta 1). [Source: SWISSPROT; Acc: P29066] 0.513
70 Neurogenic locus notch homolog protein 2 precursor (NOTCH 2). [Source: SWISSPROT; Acc: Q9QW30] 0.626
71 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10. [Source: RefSeq; Acc: NM_182671] 0.545
Table W6. (continued ).
Gene Name Ratio
72 Cyclin-dependent kinase inhibitor 2C; cyclin-dependent kinase inhibitor 2C (P18, inhibits CDK4), see also D5LEV19. [Source: RefSeq; Acc: NM_131902] 0.544
73 Neural cell adhesion molecule 1, 140 kDA isoform precursor (N-CAM 140) (NCAM-140). [Source: SWISSPROT; Acc: P13596] 0.578
74 Dihydropyrimidinase (EC 3.5.2.2) (DHPASE) (hydantoinase) (DHP). [Source: SWISSPROT; Acc: Q63150] 0.653
75 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (EC 4.1.1.32) (phosphoenolpyruvate carboxylase) (PEPCK-C). [Source: SWISSPROT; Acc: P07379] 0.550
76 Probable g protein–coupled receptor GPR19 (fragment). [Source: SWISSPROT; Acc: P70585] 0.414
77 Homeobox protein MSX-2 (HOX-8.1) (fragment). [Source: SWISSPROT; Acc: P52953] 0.547
78 Potassium voltage-gated channel subfamily KQTmember 2 (potassium channel α subunit KVLQT2) (KQT-LIKE 2). [Source: SWISSPROT; Acc: O88943] 0.649
79 Camello-like 1. [Source: RefSeq; Acc: NM_133558] 0.570
80 Adenylate cyclase, type II (EC 4.6.1.1) (ATP pyrophosphate-lyase) (adenylyl cyclase). [Source: SWISSPROT; Acc: P26769] 0.624
81 Immunoglobulin-binding protein 1 (CD79A-binding protein 1) (α4 phosphoprotein). [Source: SWISSPROT; Acc: O08836] 0.637
82 Proteasome subunit α type 7 (EC 3.4.25.1) (proteasome subunit RC6-1). [Source: SWISSPROT; Acc: P48004] 0.607
83 ADAM 7 precursor (a disintegrin and metalloproteinase domain 7) (epididymal apical protein I) (EAP I). [Source: SWISSPROT; Acc: Q63180] 0.468
84 KIAA1454-like protein (fragment). [Source: SPTREMBL; Acc: Q99MF6] 0.663
85 α-Lactalbumin precursor (lactose synthase B protein). [Source: SWISSPROT; Acc: P00714] 0.647
86 Flavin-containing monooxygenase 2. [Source: RefSeq; Acc: NM_144737] 0.559
87 Aggrecan core protein precursor (cartilage-specific proteoglycan core protein) (CSPCP). [Source: SWISSPROT; Acc: P07897] 0.639
88 Dihydrofolate reductase; dihydrofolate reductase 1 (active). [Source: RefSeq; Acc: NM_130400 0.530
89 Max-interacting protein 1 (MXI1 protein). [Source: SWISSPROT; Acc: O09015] 0.526
90 gamma Crystallin E (gamma crystallin 3-1) (gamma-2). [Source: SWISSPROT; Acc: P02528] 0.455
91 heat shock–related 70 kDA protein 2 (heat shock protein 70.2) (testis-specific heat shock protein–related) (HST). [Source: SWISSPROT; Acc: P14659] 0.466
92 Synaptobrevin-like 1. [Source: RefSeq; Acc: NM_053531] 0.605
93 DNA-binding protein A (cold shock domain protein A) (muscle Y-BOX protein YB2) (Y-BOX binding protein-A) (RYB-A). [Source: SWISSPROT; Acc: Q62764] 0.595
94 Proprotein convertase subtilisin/kexin type 1 inhibitor; granin-like neuroendocrine peptide precursor. [Source: RefSeq; Acc: NM_019279] 0.664
95 Vitronectin. [Source: RefSeq; Acc: NM_019156] 0.550
96 CYS2/HIS2 zinc finger protein (RKR1). [Source: RefSeq; Acc: NM_144757] 0.617
97 Urea transporter, kidney. [Source: SWISSPROT; Acc: Q62668] 0.616
98 Urinary protein 3 precursor (RUP-3). [Source: SWISSPROT; Acc: P83121] 0.655
99 Carcinoembryonic antigen-related protein (fragment). [Source: SPTREMBL; Acc: Q63112] 0.640
100 Growth arrest specific 6. [Source: RefSeq; Acc: NM_057100] 0.552
101 Leptin receptor gene-related protein (OB-R gene-related protein) (OB-RGRP). [Source: SWISSPROT; Acc: Q9JLS8] 0.620
102 G protein–coupled receptor 9. [Source: RefSeq; Acc: NM_053415] 0.659
103 Voltage-dependent t-type calcium channel α-1H subunit (CAV3.2). [Source: SWISSPROT; Acc: Q9EQ60] 0.597
104 Voltage-gated potassium channel subfamily H member 5 (ether-A-GO-GO potassium channel 2) (REAG2). [Source: SWISSPROT; Acc: Q9EPI9] 0.498
105 L-Serine dehydratase/L-threonine deaminase [includes: L-serine dehydratase (EC 4.3.1.17) (L-serine deaminase) (SDH); L-threonine dehydratase (EC 4.3.1.19)
(L-threonine deaminase) (TDH)]. [Source: SWISSPROT; Acc: P09367]
0.486
106 Sodium- and chloride-dependent glycine transporter 1 (GLYT1) (GLYT-1). [Source: SWISSPROT; Acc: P28572] 0.616
107 Platelet endothelial tetraspan antigen 3 (CD151 antigen). [Source: SWISSPROT; Acc: Q9QZA6] 0.572
108 YY1 transcription factor. [Source: RefSeq; Acc: NM_173290] 0.608
109 Phosphoinositol 3-phosphate-binding protein-2-like protein. [Source: SPTREMBL; Acc: Q8K481] 0.432
110 Protein phosphatase-X (EC 3.1.3.16) (serine/threonine protein phosphatase) (fragment). [Source: SPTREMBL; Acc: Q04104] 0.596
111 Visinin-like protein 2 (VILIP-2) (neural visinin-like protein 2) (NVL-2) (NVP-2). [Source: SWISSPROT; Acc: P35332] 0.622
112 Cytochrome P450 2E1 (EC 1.14.14.1) (CYPIIE1) (P450-J) (P450RLM6). [Source: SWISSPROT; Acc: P05182] 0.595
113 Gap junction channel protein connexin47 (fragment). [Source: SPTREMBL; Acc: Q80XF7] 0.604
114 Zinc finger protein 384 (nuclear matrix transcription factor 4) (CAS-associated zinc finger protein). [Source: SWISSPROT; Acc: Q9EQJ4] 0.652
115 Huntingtin-associated protein-interacting protein (duo protein) (kalirin) (PAM COOH-terminal interactor protein 10) (P-CIP10). [Source: SWISSPROT; Acc: P97924 0.562
116 Actinfilin. [Source: RefSeq; Acc: NM_145671] 0.517
117 Glutamate receptor, ionotropic kainate 5 precursor (glutamate receptor KA-2) (KA2). [Source: SWISSPROT; Acc: Q63273 0.627
118 Glutaminase, kidney isoform, mitochondrial precursor (EC 3.5.1.2) (GLS) (L-glutamine amidohydrolase) (K-glutaminase). [Source: SWISSPROT; Acc: P13264] 0.658
119 Guanine nucleotide-binding protein G(OLF), α subunit (adenylate cyclase-stimulating G α protein, olfactory type). [Source: SWISSPROT; Acc: P38406] 0.597
120 Chloride intracellular channel protein 5. [Source: SWISSPROT; Acc: Q9EPT8] 0.418
121 Prolyl endopeptidase. [Source: RefSeq; Acc: NM_031324] 0.438
122 RAB6-interacting protein 2; RIM-binding protein; ELKS. [Source: RefSeq; Acc: NM_170788] 0.590
123 Dynein-like protein 10 (fragment). [Source: SPTREMBL; Acc: Q63161] 0.392
124 Thymidine kinase, cytosolic (EC 2.7.1.21) (fragment). [Source: SWISSPROT; Acc: P27158] 0.660
125 Zinc finger and homeodomain protein 1. [Source: RefSeq; Acc: NM_133620] 0.459
126 Regulator of G-protein signaling 6 (RGS6) (fragment). [Source: SWISSPROT; Acc: P49801] 0.591
127 Chondroitin sulfate proteoglycan NG2 precursor (HSN tumor-specific antigen). [Source: SWISSPROT; Acc: Q00657] 0.577
128 Epimorphin (syntaxin 2). [Source: SWISSPROT; Acc: P50279] 0.492
129 α-1D Adrenergic receptor (α 1d-adrenoceptor) (α-1a adrenergic receptor) (RA42). [Source: SWISSPROT; Acc: P23944] 0.623
130 Enoyl-CoA hydratase, mitochondrial precursor (EC 4.2.1.17) (short chain enoyl-CoA hydratase) (SCEH) (enoyl-CoA hydratase 1). [Source: SWISSPROT; Acc: P14604] 0.458
131 RAT AXL shortform. [Source: SPTREMBL; Acc: Q8VI99] 0.658
132 Calcium/calmodulin–dependent protein kinase II subtype delta 5 (fragment). [Source: SPTREMBL; Acc: Q63907] 0.630
133 Valosin-containing protein (P97)/P47 complex-interacting protein P135; VCP(P97)/P47-interacting protein. [Source: RefSeq; Acc: NM_176857] 0.541
134 Glutathione S -transferase YRS-YRS (EC 2.5.1.18) (GST 12-12) (glutathione S -transferase subunit 12) (GST class-THETA). [Source: SWISSPROT; Acc: P30713] 0.659
135 6-Phosphofructokinase, type C (EC 2.7.1.11) (phosphofructokinase 1) (phosphohexokinase) (phosphofructo-1-kinase isozyme C) (PFK-C) (fragment). [Source: SWISSPROT;
Acc: P47860]
0.570
136 GDNF family receptor α4 precursor (GFR-α4) (GFRALPHA4) (persephin receptor). [Source: SWISSPROT; Acc: Q9EPI2] 0.558
137 Heterogeneous nuclear ribonucleoprotein R. [Source: RefSeq; Acc: NM_175603] 0.635
138 Membrane glycoprotein. [Source: RefSeq; Acc: NM_020081] 0.488
139 Nuclear factor 1 A-type (nuclear factor 1/A) (NF1-A) (NFI-A) (NF-I/A) (CCAAT-BOX binding transcription factor) (CTF) (TGGCA-binding protein). [Source: SWISSPROT;
Acc: P09414]
0.519
140 Monocyte differentiation antigen CD14 precursor (myeloid cell–specific leucine-rich glycoprotein). [Source: SWISSPROT; Acc: Q63691] 0.563
141 Cytochrome P450 2A2 (EC 1.14.14.1) (CYPIIA2) (testosterone 15-α-hydroxylase) (P450-UT-4). [Source: SWISSPROT; Acc: P15149] 0.485
142 Neuronal acetylcholine receptor protein, α-2 chain precursor. [Source: SWISSPROT; Acc: P12389] 0.639
Table W6. (continued ).
Gene Name Ratio
143 Augmenter of liver regeneration. [Source: SWISSPROT; Acc: Q63042] 0.421
144 ATP-binding cassette, subfamily C (CFTR/MRP), member 3. [Source: RefSeq; Acc: NM_080581] 0.512
145 Yotiao protein (fragment). [Source: SPTREMBL; Acc: Q9JHE0] 0.637
146 Striatin. [Source: SWISSPROT; Acc: P70483] 0.574
147 Plasminogen activator inhibitor-2, type A (PAI2A) (PAI-2). [Source: SWISSPROT; Acc: P29524] 0.502
148 Forkhead box protein G1A (forkhead-related protein FKHL2) (transcription factor BF-2) (brain factor 2) (BF2) (fragment). [Source: SWISSPROT; Acc: Q63251] 0.527
149 α-2U globulin PGCL3. [Source: RefSeq; Acc: NM_147212] 0.522
150 Acyl coenzyme A thioester hydrolase, mitochondrial precursor (EC 3.1.2.2) (very-long-chain acyl-CoA thioesterase) (MTE-I). [Source: SWISSPROT; Acc: O55171] 0.630
151 Thioredoxin-like (32KD). [Source: RefSeq; Acc: NM_080887] 0.638
152 cAMP-dependent protein kinase, α-catalytic subunit (EC 2.7.1.37) (PKA C-α). [Source: SWISSPROT; Acc: P27791] 0.651
153 40S ribosomal protein S3A (V-fos transformation effector protein). [Source: SWISSPROT; Acc: P49242] 0.597
154 Rabphilin-3A (exophilin 1). [Source: SWISSPROT; Acc: P47709] 0.664
155 Neogenin precursor (fragment). [Source: SWISSPROT; Acc: P97603] 0.520
156 Degenerative spermatocyte homolog. [Source: RefSeq; Acc: NM_053323] 0.346
157 sirtuin 2 (silent mating type information regulation 2, homolog) 2; 5E5 antigen. [Source: RefSeq; Acc: NM_053737] 0.564
158 Nuclear GTPase pike. [Source: RefSeq; Acc: NM_023026] 0.503
159 Mucin 1 (fragment). [Source: SPTREMBL; Acc: O35770] 0.551
160 Protease, serine, 12; protease, serine, 12 neurotrypsin (motopsin). [Source: RefSeq; Acc: NM_053504] 0.620
161 C-ETS-1 protein (P54). [Source: SWISSPROT; Acc: P41156] 0.591
162 VIP-receptor transcriptional repressor protein (VIPR-RP). [Source: SPTREMBL; Acc: O88461] 0.642
163 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma 1 (EC 3.1.4.11) (phosphoinositide phospholipase C) (PLC-gamma-1) (phospholipase C-gamma-1) (PLC-II)
(PLC-148). [Source: SWISSPROT; Acc: P10686]
0.596
164 ATP-binding cassette, subfamily A (ABC1), member 5. [Source: RefSeq; Acc: NM_173307] 0.608
165 Interleukin-1 beta precursor (IL-1 beta). [Source: SWISSPROT; Acc: Q63264] 0.664
166 Forkhead box protein C2 (brain factor-3) (BF-3) (HFH-BF-3) (fragment). [Source: SWISSPROT; Acc: Q63246] 0.580
167 α-2 Antiplasmin; pigment epithelium-derived factor. [Source: RefSeq; Acc: NM_177927] 0.452
168 Aldehyde dehydrogenase 1A2 (EC 1.2.1.3) (retinaldehyde-specific dehydrogenase type 2) (RALDH(II)) (RALDH-2). [Source: SWISSPROT; Acc: Q63639] 0.622
169 Solute carrier family 38, member 2; amino acid transporter, cationic 2 (low affinity); amino acid transporter system A2. [Source: RefSeq; Acc: NM_181090] 0.622
170 Glial cell line–derived neurotrophic factor precursor. [Source: SWISSPROT; Acc: Q07731] 0.652
171 Receptor tyrosine kinase. [Source: SPTREMBL; Acc: Q9EPA1] 0.577
172 Serine/threonine protein phosphatase 2A, 55-kDA regulatory subunit B, α isoform (PP2A, subunit B, B-alpha isoform) (PP2A, subunit B, B55-alpha isoform) (PP2A, subunit B,
PR55-alpha isoform) (PP2A, subunit B, R2-alpha isoform) [Source: SWISSPROT; Acc: P36876]
0.611
173 Vesicle-associated membrane protein 8 (endobrevin). [Source: RefSeq; Acc: NM_031827] 0.518
174 Claudin-7 (fragment). [Source: SWISSPROT; Acc: Q9Z1L1] 0.643
175 XRCC5 (fragment). [Source: SPTREMBL; Acc: Q8VIB0] 0.618
176 cAMP-dependent protein kinase type II-alpha regulatory chain (fragment). [Source: SWISSPROT; Acc: P12368] 0.631
177 GTP-binding protein REM2; ras-related GTP-binding protein of the RAD/GEM/KIR family; ras-related GTP-binding protein of the RAD/GEM/KIR family, member 2.
[Source: RefSeq; Acc: NM_022685]
0.578
178 40S ribosomal protein S9. [Source: SWISSPROT; Acc: P29314] 0.660
179 Histone H2A, testis. [Source: SWISSPROT; Acc: Q00728] 0.519
180 Voltage-dependent P/Q-type calcium channel α-1A subunit (calcium channel, L type, α-1 polypeptide, isoform 4) (brain calcium channel I) (BI) (rat brain class A) (RBA-I).
[Source: SWISSPROT; Acc: P54282]
0.559
181 Cathepsin K precursor (EC 3.4.22.38). [Source: SWISSPROT; Acc: O35186] 0.548
182 Werner syndrome homolog (human) interacting protein. [Source: RefSeq; Acc: NM_172332] 0.619
183 NADP-dependent malic enzyme (EC 1.1.1.40) (NADP-ME) (malic enzyme 1). [Source: SWISSPROT; Acc: P13697] 0.637
184 Dihydropyrimidinase related protein-1 (DRP-1) (collapsin response mediator protein 1) (CRMP-1). [Source: SWISSPROT; Acc: Q62950] 0.586
185 Heat shock 27 kDA protein (HSP 27). [Source: SWISSPROT; Acc: P42930] 0.539
186 Zinc finger protein 94 (ZFP-94) (zinc finger protein Y1) (RLZF-Y). [Source: SWISSPROT; Acc: Q9Z2K3] 0.579
187 Cytochrome P450 2B1 (EC 1.14.14.1) (CYPIIB1) (P450-B) (P450-PB1 and P450-PB2) (P450-LM2). [Source: SWISSPROT; Acc: P00176] 0.657
This list was selected with Bioplot (Web site of Biopuce) downregulated threshold = 0.66, P < .05 with Student’s t test.
